Related Experiment Video

Updated: Aug 19, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferons in relapsing remitting MS: a systematic review comments on a meta-analysis

M Clanet1, M Cucheratt

  • 1Service de Neurologie, CHU Toulouse Purpan, Toulouse, France.

International MS Journal
|February 24, 2004
PubMed

Insights

Recombinant interferons show uncertain clinical effects beyond one year in relapsing-remitting multiple sclerosis (RRMS). Further long-term trials are necessary to confirm their effectiveness in managing RRMS.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Recombinant interferons are a major therapeutic class for relapsing-remitting multiple sclerosis (RRMS).
  • Recent systematic reviews question the long-term clinical efficacy of these treatments beyond one year.
  • The MS community requires clarity on the sustained benefits of interferon therapy.

Purpose of the Study:

  • To address the uncertainty surrounding the long-term effectiveness of recombinant interferons in RRMS.
  • To provide an explanation for patients and neurologists regarding the clinical utility of these therapies.

Main Methods:

  • Systematic review of major therapeutic recombinant interferon trials in RRMS.
  • Analysis of reported clinical effects beyond the one-year mark.

Main Results:

  • The clinical effect of recombinant interferons in RRMS beyond one year was found to be uncertain.
  • The need for new trials to assess long-term effectiveness was highlighted.

Conclusions:

  • The long-term effectiveness of recombinant interferons in RRMS requires further investigation through extended trials.
  • Patients and clinicians need a comprehensive understanding of treatment benefits beyond initial assessments.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...